Mayelana noDokotela
UDkt Ahn Jin-hee uphakathi kwesazi somdlavuza esihamba phambili eSeoul, eNingizimu Korea.
- UDkt Ahn Jin-hee imfundo
-
- Udokotela Wezokwelapha: University of Ulsan
- I-Master of Medicine: Inyuvesi yase-Ulsan
- IBachelor of Medicine: IHanyang University
- UDkt. Ahn Jin-hee okuhlangenwe nakho kobuchwepheshe
-
- Umcwaningi ovakashele esikhungweni seCanafaber Cancer, eHarvard Medical School, e-USA
- Hlanganisa uSolwazi ku-Oncology, e-UUCM AMC
- Umsizi uProfesa ku-Oncology, i-UUCM AMC
- Umfundisi Wezokwelapha e-UUCM AMC
- Ukubambisana ku-UUCM AMC
- Ukuhlala kabusha e-UUCM AMC
- Umsebenzi ku-UUCM AMC
Isibhedlela
Isikhungo Sezokwelapha i-Asan, eSeoul, eNingizimu Korea
Ubuchwepheshe
- Umdlavuza wesibeletho
- I-sarcoma yamathambo nezithambile
- umdlavuza womlomo wesibeletho
- Umdlavuza wesitho sangasese sowesifazane
- Umdlavuza we-Ovarian
Izinqubo ezenziwayo
- Ukwelashwa umdlavuza webele
- Ukwelashwa kwamathambo nezicubu ezithambile ze-sarcoma
- Ukwelashwa komdlavuza wesibeletho
- Ukwelashwa komdlavuza wesitho sangasese sowesifazane
- Ukwelashwa komdlavuza we-Ovarian
Ucwaningo Nokushicilelwa
| Inhlanganisela ye-Gemcitabine ne-Docetaxel ye-Advanced Soft Tissue Sarcoma: Isifundo Esibuyela Kuzwe Lonke. |
| Isigaba III, Isifundo Esenziwe Ngokungahleliwe, Esingaboni Ngamehlo Ukuqhathanisa Ukusebenza Kokuphepha, Ukuphepha, kanye Nokungasebenzi komzimba kwe-SB3 (iTrastuzumab Biosimilar) kanye neReferensi yeTrastuzumab ezigulini ezelashwa ngeNeoadjuvant Therapy yeHuman Epidermal Growth Factor Receptor 2-Positive |
| Ucwaningo Lokungenzeka Ngokungahleliwe lwe- (18) F-Fluoroestradiol PET Ukubikezela Impendulo YePathologic kuNeoadjuvant Therapy e-Estrogen Receptor-Rich Postmenopausal Cancer Cancer. |
| Isigaba I sokukhuphuka kwesilinganiso sokwanda kwe-c-Met tyrosine kinase inhibitor SAR125844 ezigulini zase-Asia ezinamathumba aqinile athuthukile, kufaka phakathi iziguli ezinomdlavuza we-MET-amplified gastric. |
| Isigaba II, i-multicentre, isilingo esingahleliwe se-eribulin kanye ne-gemcitabine kuqhathaniswa ne-paclitaxel kanye ne-gemcitabine njenge-chemotherapy yomugqa wokuqala ezigulini ezinomdlavuza webele we-HER2-negative. |
| Izinga lokuphila ku-TSU-68: Inhlanganisela ye-docetaxel ne-TSU-68, i-ejenti yomlomo ye-antiangiogenic, ezigulini ezinomdlavuza webele we-metastatic ngaphambili owawelashwa nge-anthracycline. |
| Ucwaningo olwenzeka ngokungahleliwe lwe-18F-fluoroestradiol positron emission tomography ukubikezela ukuphendula kwe-pathological ku-neoadjuvant systemic therapy ku-estrogen receptor-rich postmenopausal cancer. |
| Isisho seCytoplasmic seqembu lokuhamba eliphakeme le-B1 (HMGB1) lihlotshaniswa nama-lymphocyte angena isimila (TILs) kumdlavuza webele. |
| Imiphumela yesikhathi eside yokuqedwa kwe-tyrosine kinase inhibitor ezigulini ezine-metastatic renal cell carcinoma. |
| Ukunqunywa kweMonogenic kanye ne-polygenic yengozi ye-sarcoma: isifundo somhlaba jikelele sezofuzo. |
| Ukulandelana kwesizukulwane esilandelayo kuveza ukuguquka kwesimo somzimba okunikeza impendulo ehlukile ku-everolimus. |
| Isivivinyo sesiGaba II se-neoadjuvant letrozole ne-lapatinib kwabesifazane base-Asia abangemva kokuya esikhathini nokuthola i-estrogen receptor (ER) kanye nomdlavuza webele we-epidermal growth factor receptor 2 (HER2) -umdlavuza webele obonakalayo [Neo-ALL-IN]: Ukugqamisa ama-TILs, u-ER ushintsho lokuveza aft |
| I-Radiotherapy Yangemva Kokuhlinzwa Ngemuva Kokuhlinzwa Kokulondolozwa Kwezitho Zomzimba Kwama-Soft-tissue Sarcomas we-Distal Extremities |
| Ucwaningo lwesigaba 1 somuthi wokugoma we-heterologous prime-boost ohilela ukulandelana okuncishisiwe kwe-HER2 ezigulini ezinomdlavuza webele we-HER2. |
| Ukusabalalisa ama-Plasma Biomarkers we-TSU-68, i-Oral Antiangiogenic Agent, ezigulini ezinomdlavuza webele weMetastatic. |
| Ukubaluleka Kwe-Clinicopathologic kwe-Intratumoral Heterogeneity ye-HER2 Gene Amplification ku-HER2-Positive Iziguli Zomdlavuza Webele Zelashwa Nge-Adjuvant Trastuzumab |
| Ukuqhathaniswa kwamaPathologic Response Evaluation Systems ngemuva kwe-Anthracycline nge / ngaphandle kweTaxane-based Neoadjuvant Chemotherapy phakathi kwezinhlobo ezahlukahlukene zomdlavuza webele. |
| Ukuhamba okuphezulu kweqembu B1 kanye ne-N1 (HMGB1 ne-HMGN1) kuhlotshaniswa nama-lymphocyte angena esiswini kuma-cancer e-HER2-positive |
| Ukubaluleka kokubikezela kwamaLymphocyte angena ngaphakathi emathunjini kanye Nezakhiwo Eziphezulu ZeLymphoid ku-HER2-Positive Cancer Cancer Ephethwe Nge-Adjuvant Trastuzumab. |
| Ukuhlola izicubu ze-biomarker ezigulini ezine-metastatic renal cell carcinoma ethola i-vascular endothelial growth factor receptor tyrosine kinase inhibitors. |
